INmune Bio, Inc.

Equities

INMB

US45782T1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
10.02 ^USD	-6.96%		-13.40%	-11.01%

May. 09	Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000	MT
May. 09	INmune Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

INMUNE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

March 22, 2021 at 04:05 pm EDT

Item 8.01. Other Events.

On March 22, 2021, INmune Bio Inc., a Nevada corporation (the "Company"), issued a press release announcing that Professor Mark Lowdell will be delivering presentations at two upcoming medical meetings. A copy of this press release is attached as Exhibit 99.1

Item 9.01 Financial statements and Exhibits





(d) Exhibits.



Exhibit
Number    Description
99.1        Press Release dated March 22, 2021

Latest news about INmune Bio, Inc.

Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000	May. 09	MT
INmune Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial	Apr. 30	CI
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune?? Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	Apr. 29	CI
Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro? for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	Apr. 23	CI
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	Apr. 08	CI
Transcript : INmune Bio, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
INmune Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro	Mar. 05	CI
FDA Lifts Clinical Hold on INmune Bio Alzheimer's Program	Jan. 30	DJ
Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer?S Disease Program	Jan. 30	CI
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology	Jan. 16	CI
Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc..	Jan. 15	CI
INmune Bio, Inc. Announces First Patient Dosed in Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer	Jan. 02	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	Dec. 19	MT
Looming Inflation Data Stifle US Equity Futures Pre-Bell	Dec. 19	MT
Sector Update: Health Care	Dec. 19	MT
INmune Bio Shares Drop as Alzheimer's Treatment Study Remains on Hold	Dec. 19	DJ
Top Premarket Decliners	Dec. 19	MT
INmune Bio Alzheimer's Treatment Remains on Clinical Hold After FDA Requests Information; Shares Slump After Hours	Dec. 18	MT
INmune Bio Alzheimer's Treatment Study to Remain on Clinical Hold	Dec. 18	DJ
INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA	Dec. 18	CI
Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium	Nov. 29	CI
INmune Bio Gets Authorization in France, Spain for Phase II Trial of XPro for Early Alzheimer's Disease	Nov. 27	MT
INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease	Nov. 27	CI

Chart INmune Bio, Inc.

Duration

Period

More charts

Company Profile

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for INmune Bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.02 USD

Average target price

19.67 USD

Spread / Average Target

+96.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INMUNE BIO, INC.	-11.01%	198M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs